EUVIMEDEUVIMED entdecken
Crossref

Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs

Liesl K Janssens iD, Katleen Van Uytfanghe iD, Jeffrey B Williams, Kirk W Hering, Donna M Iula, Christophe P Stove iD

Archives of Toxicology · 2024-08 · 98 (8) · 2619-2630

DOI: 10.1007/s00204-024-03769-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archives of Toxicology, online erschienen am 12.05.2024. Verfasst von Liesl K Janssens und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Toxicology, Department of Bioanalysis - Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. Hauptthemen laut MEDLINE: Cannabinoids, Cannabis, beta-Arrestin 2. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Bijzonder Onderzoeksfonds UGent.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cultivation of industrial low-Δ9-tetrahydrocannabinol (Δ9-THC) hemp has created an oversupply of cannabidiol (CBD)-rich products. The fact that phytocannabinoids, including CBD, can be used as precursors to synthetically produce a range of THC variants-potentially located in a legal loophole-has led to a diversification of cannabis recreational drug markets. 'Hemp-compliant', 'hemp-derived' and 'semisynthetic' cannabinoid products are emerging and being advertised as (legal) alternatives for Δ9-THC. This study included a large panel (n = 30) of THC isomers, homologs, and analogs that might be derived via semisynthetic procedures. As a proxy for the abuse potential of these compounds, we assessed their potential to activate the CB1 cannabinoid receptor with a β-arrestin2 recruitment bioassay (picomolar-micromolar concentrations). Multiple THC homologs (tetrahydrocannabihexol, THCH; tetrahydrocannabiphorol, THCP; tetrahydrocannabinol-C8, THC-C8) and THC analogs (hexahydrocannabinol, HHC; hexahydrocannabiphorol, HHCP) were identified that showed higher potential for CB1 activation than Δ9-THC, based on either higher efficacy (Emax) or higher potency (EC50). Structure-activity relationships were assessed for Δ9-THC and Δ8-THC homologs encompassing elongated alkyl chains. Additionally, stereoisomer-specific differences in CB1 activity were established for various THC isomers (Δ7-THC, Δ10-THC) and analogs (HHC, HHCP). Evaluation of the relative abundance of 9(S)-HHC and 9(R)-HHC epimers in seized drug material revealed varying epimeric compositions between batches. Increased abundance of the less active 9(S)-HHC epimer empirically resulted in decreased potency, but sustained efficacy for the resulting diastereomeric mixture. In conclusion, monitoring of semisynthetic cannabinoids is encouraged as the dosing and the relative composition of stereoisomers can impact the harm potential of these drugs, relative to Δ9-THC products.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabinoidsCannabisbeta-Arrestin 2HEK293 CellsHumansStructure-Activity RelationshipIsomerismReceptor, Cannabinoid, CB1Biological Assay

Stichwörter der Autor:innen

BioassayHHCPharmacological characterizationPhytocannabinoidsSemisynthetic cannabinoidsToxicology

Substanzen

Cannabinoidsbeta-Arrestin 2ARRB2 protein, humanReceptor, Cannabinoid, CB1

Autor:innen und Institutionen

  • Laboratory of Toxicology, Department of Bioanalysis - Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium.
  • Forensic Chemistry Division, Cayman Chemical Company, Ann Arbor, MI, 48108, USA.
  • Laboratory of Toxicology, Department of Bioanalysis - Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. christophe.stove@ugent.be.

ORCID-Profile: Liesl K Janssens, Katleen Van Uytfanghe, Christophe P Stove

Förderung

  • Bijzonder Onderzoeksfonds UGent

Zitieren

APA

Janssens, L. K., Van Uytfanghe, K., Williams, J. B., Hering, K. W., Iula, D. M., & Stove, C. P. (2024). Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs. Archives of Toxicology, 98(8), 2619-2630. https://doi.org/10.1007/s00204-024-03769-4

Vancouver

Janssens LK, Van Uytfanghe K, Williams JB, Hering KW, Iula DM, Stove CP. Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs. Archives of Toxicology. 2024;98(8):2619-2630. doi:10.1007/s00204-024-03769-4

BibTeX
@article{Janssens2024,
  author = {Janssens, Liesl K and Van Uytfanghe, Katleen and Williams, Jeffrey B and Hering, Kirk W and Iula, Donna M and Stove, Christophe P},
  title = {Investigation of the intrinsic cannabinoid activity of hemp-derived and semisynthetic cannabinoids with β-arrestin2 recruitment assays—and how this matters for the harm potential of seized drugs},
  journal = {Archives of Toxicology},
  year = {2024},
  volume = {98},
  number = {8},
  pages = {2619--2630},
  doi = {10.1007/s00204-024-03769-4}
}
Kostenlos starten →